Cannabinoids Showed Significant Neuroprotective Effects in Animal Models of Stroke | Research

The takeaway

A meta-analysis of 26 animal studies found that cannabinoids, especially CBD, reduced brain damage after stroke through multiple mechanisms including reducing inflammation, oxidative stress, and cell death.

Researchers and anyone interested in potential future medical applications of cannabinoids for stroke treatment.

Cannabinoids improved 9 outcome measures including infarct volume, neurological function, and inflammation

What the researchers found

Across 26 studies, cannabinoids significantly reduced cerebral infarct volume, improved neurological function, increased cerebral blood flow, and decreased blood-brain barrier permeability, brain water content, cell death, oxidative stress markers, and inflammatory markers (TNF-alpha, IL-1beta). Subgroup analysis showed CBD administered intraperitoneally throughout the full course produced the best results with less variability.

Why it matters

Ischemic stroke has very few treatment options. This comprehensive analysis of animal research suggests cannabinoids, particularly CBD, may work through multiple protective pathways, building the case for moving toward human clinical trials.

The numbers in context

241 publications identified for bibliometric analysis. 26 studies included in meta-analysis. Three major research topics identified through keyword analysis. CBD via intraperitoneal administration showed enhanced benefit with reduced heterogeneity. Significant improvements across 9 outcome measures.

How the study worked

Systematic review with meta-analysis combining bibliometric analysis (241 publications) and quantitative synthesis of 26 preclinical studies on cannabinoids in animal models of ischemic stroke. Pooled standardized mean differences with 95% confidence intervals were calculated with subgroup analyses.

What this study cannot tell us

All evidence comes from animal models, which may not translate directly to humans. Publication bias may favor positive results. Heterogeneity in protocols across studies, though subgroup analysis helped address this.

How to read the evidence

Moderate: rigorous meta-analysis with subgroup analysis, but entirely based on animal models with no human clinical data.

When this study was published

2025 study analyzing literature through June 2025.

The bigger picture

Research on cannabinoids for stroke has been growing steadily since 2000. This meta-analysis consolidates the preclinical evidence and identifies the most promising approaches (CBD, specific administration routes) to guide future clinical translation.

Questions still open

Will these neuroprotective effects hold up in human stroke patients? What is the optimal timing of cannabinoid administration relative to stroke onset? What dose would be needed in humans?

Common questions

Which cannabinoid worked best for stroke?

CBD administered intraperitoneally through the full treatment course was associated with the most consistent benefits and least variability across studies.

How do cannabinoids protect the brain during stroke?

Through multiple mechanisms: improving blood flow, reducing swelling, protecting the blood-brain barrier, fighting oxidative stress, reducing inflammation, and preventing cell death.

Read the original research

Exploring the neuroprotective effects and underlying mechanisms of medical cannabinoids in ischemic stroke: a systematic meta-analysis with bibliometric mapping of cerebral ischemia research.

Frontiers in neuroscience, 19, 1731738

View on PubMed ↗Publisher’s paper ↗

Citation

Li, Xiaoqun; Wen, Lulu; Du, Yun; Fan, Xinyue; Xue, Ningyu; Qu, Miao. (2025). Exploring the neuroprotective effects and underlying mechanisms of medical cannabinoids in ischemic stroke: a systematic meta-analysis with bibliometric mapping of cerebral ischemia research.. Frontiers in neuroscience, 19, 1731738. https://doi.org/10.3389/fnins.2025.1731738